Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate GeneDx Holdings Corp. before investing.

In this article, we go over a few key elements for understanding GeneDx Holdings Corp.’s stock price such as:

• GeneDx Holdings Corp.’s current stock price and volume
• Why GeneDx Holdings Corp.’s stock price changed recently
• Upgrades and downgrades for WGS from analysts
• WGS’s stock price momentum as measured by its relative strength

About GeneDx Holdings Corp. (WGS)

Before we jump into GeneDx Holdings Corp.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx Holdings Corp. was founded in 2000 and is headquartered in Stamford, Connecticut.

Want to learn more about GeneDx Holdings Corp.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about GeneDx Holdings Corp..

GeneDx Holdings Corp.’s Stock Price as of Market Close

As of July 31, 2026, 11:30 AM, CST, GeneDx Holdings Corp.’s stock price was $65.795.

GeneDx Holdings Corp. is down 4.59% from its previous closing price of $68.960.

During the last market session, GeneDx Holdings Corp.’s stock traded between $65.390 and $70.830. Currently, there are approximately 29.34 million shares outstanding for GeneDx Holdings Corp..

GeneDx Holdings Corp.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

GeneDx Holdings Corp. Stock Price History

GeneDx Holdings Corp.’s (WGS) price is currently down 4.16% so far this month.

During the month of July, GeneDx Holdings Corp.’s stock price has reached a high of $72.950 and a low of $58.140.

Over the last year, GeneDx Holdings Corp. has hit prices as high as $170.870 and as low as $32.210. Year to date, GeneDx Holdings Corp.’s stock is down 49.41%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused GeneDx Holdings Corp. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 30, 2026, there were 0 analysts who downgraded GeneDx Holdings Corp.’s stock and 2 analysts who upgraded over the last month.

Additionally, you'll want to evaluate GeneDx Holdings Corp.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on GeneDx Holdings Corp.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

GeneDx Holdings Corp.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about GeneDx Holdings Corp. (WGS) by visiting AAII Stock Evaluator.

Relative Price Strength of GeneDx Holdings Corp.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 30, 2026, GeneDx Holdings Corp. has a weighted four-quarter relative price strength of -6.48%, which translates to a Momentum Score of 31 and is considered to be Weak.

Want to learn more about how GeneDx Holdings Corp. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

GeneDx Holdings Corp. Stock Price: Bottom Line

As of July 31, 2026, GeneDx Holdings Corp.’s stock price is $65.795, which is down 4.59% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like GeneDx Holdings Corp. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.